

# Patrick N Harter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/253729/publications.pdf>

Version: 2024-02-01

90  
papers

4,780  
citations

172457

29  
h-index

110387

64  
g-index

90  
all docs

90  
docs citations

90  
times ranked

10339  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	282
3	Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 39-57.	6.9	140
4	Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. <i>Acta Neuropathologica</i> , 2015, 129, 115-131.	7.7	122
5	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
6	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018, 135, 955-963.	7.7	109
7	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. <i>Oncotarget</i> , 2015, 6, 40836-40849.	1.8	106
8	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	7.7	104
9	Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. <i>Brain Pathology</i> , 2019, 29, 513-529.	4.1	99
10	MIF Receptor CD74 is Restricted to Microglia/Macrophages, Associated with a Polarized Immune Milieu and Prolonged Patient Survival in Gliomas. <i>Brain Pathology</i> , 2015, 25, 491-504.	4.1	90
11	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . <i>Neuro-Oncology</i> , 2021, 23, 34-43.	1.2	75
12	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. <i>Cancer Immunology Research</i> , 2019, 7, 1910-1927.	3.4	74
13	Classification of meningiomas—advances and controversies. <i>Chinese Clinical Oncology</i> , 2017, 6, S2-S2.	1.2	66
14	Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas. <i>Neurosurgery</i> , 2019, 84, 190-197.	1.1	59
15	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. <i>Oncology Letters</i> , 2017, 14, 1141-1146.	1.8	58
16	Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2298-2313.	0.9	56
17	Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. <i>Acta Neuropathologica</i> , 2016, 132, 479-481.	7.7	54
18	BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1281-1294.	4.3	53

#	ARTICLE	IF	CITATIONS
19	β2-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma. <i>Molecular Cancer</i> , 2015, 14, 17.	19.2	51
20	The angiogenic switch leads to a metabolic shift in human glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now175.	1.2	50
21	ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 987-995.	0.8	46
22	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. <i>Oncology Reports</i> , 2017, 38, 3291-3296.	2.6	46
23	The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. <i>British Journal of Cancer</i> , 2019, 120, 481-487.	6.4	45
24	Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581.	7.7	45
25	Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 137, 503-510.	2.9	37
26	The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. <i>Neuro-Oncology</i> , 2022, 24, 213-225.	1.2	36
27	Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence. <i>Journal of Neuroimaging</i> , 2016, 26, 116-123.	2.0	35
28	Downstream effects of plectin mutations in epidermolysis bullosa simplex with muscular dystrophy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 44.	5.2	35
29	Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. <i>Neuro-Oncology</i> , 2016, 18, 173-183.	1.2	35
30	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	7.7	33
31	Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. <i>Brain</i> , 2017, 140, 2623-2638.	7.6	30
32	Netrin-1 Expression Is an Independent Prognostic Factor for Poor Patient Survival in Brain Metastases. <i>PLoS ONE</i> , 2014, 9, e92311.	2.5	28
33	Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. <i>Neurology</i> , 2014, 83, 227-234.	1.1	28
34	Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma. <i>Oncotarget</i> , 2015, 6, 14537-14544.	1.8	27
35	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6993.	4.1	26
36	DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma. , 2021, 9, e002226.		26

#	ARTICLE	IF	CITATIONS
37	Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1504.	4.1	25
38	Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception. <i>Nature Communications</i> , 2017, 8, 15922.	12.8	24
39	Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 2031.	2.4	23
40	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 2488-2495.	8.2	23
41	Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 81.	5.2	22
42	Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 331-334.	7.7	22
43	Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model. <i>Cancers</i> , 2019, 11, 333.	3.7	22
44	AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2924-2943.	9.4	20
45	Disruption of peroxisome proliferator-activated receptor $\beta$ coactivator (PGC)-1 $\alpha$ reverts key features of the neoplastic phenotype of glioma cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 3037-3050.	3.4	18
46	Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 326-336.	1.2	18
47	IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3027.	4.1	17
48	Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial. <i>European Journal of Nutrition</i> , 2022, 61, 477-487.	3.9	16
49	Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors. <i>PLoS ONE</i> , 2015, 10, e0127123.	2.5	15
50	Anti-tissue factor (TF) treatment reduces tumor cell invasiveness in a novel migratory glioma model. <i>Neuropathology</i> , 2013, 33, 515-525.	1.2	13
51	Two is not enough: Impact of the number of tissue samples obtained from stereotactic brain biopsies in suspected glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2018, 47, 311-314.	1.5	13
52	Mid-Gestation lethality of Atxn2l-Ablated Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5124.	4.1	13
53	Early and Late Postoperative Seizures in Meningioma Patients and Prediction by a Recent Scoring System. <i>Cancers</i> , 2021, 13, 450.	3.7	13
54	Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid. <i>PLoS ONE</i> , 2014, 9, e94921.	2.5	13

#	ARTICLE	IF	CITATIONS
55	Bevacizumab for Patients with Recurrent Multifocal Glioblastomas. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2469.	4.1	12
56	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	5.2	12
57	Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux. <i>Oncotarget</i> , 2017, 8, 67567-67591.	1.8	11
58	New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact. <i>Journal of Neurology</i> , 2018, 265, 647-658.	3.6	11
59	Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma. <i>Cancer Research</i> , 2018, 78, 1935-1947.	0.9	11
60	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	7.7	11
61	Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 434.	8.6	11
62	Influence of pregnancy on glioma patients. <i>Acta Neurochirurgica</i> , 2019, 161, 535-543.	1.7	11
63	Expression Profile of Sonic Hedgehog Pathway Members in the Developing Human Fetal Brain. <i>BioMed Research International</i> , 2015, 2015, 1-15.	1.9	10
64	ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	10
65	C5b-9 deposits on endomysial capillaries in non-dermatomyositis cases. <i>Neuromuscular Disorders</i> , 2016, 26, 283-291.	0.6	10
66	Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4267.	4.1	10
67	Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. <i>Cancers</i> , 2020, 12, 3549.	3.7	9
68	Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma. <i>Journal of Neurochemistry</i> , 2018, 144, 421-430.	3.9	8
69	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. <i>Pathology Research and Practice</i> , 2020, 216, 152728.	2.3	8
70	Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. <i>Journal of Molecular Histology</i> , 2021, 52, 233-243.	2.2	8
71	Clinical Outcome and Risk Factors of Red Blood Cell Transfusion in Patients Undergoing Elective Primary Meningioma Resection. <i>Cancers</i> , 2021, 13, 3601.	3.7	8
72	Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma. <i>Oncotarget</i> , 2018, 9, 24041-24053.	1.8	8

#	ARTICLE	IF	CITATIONS
73	Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases. <i>Journal of Clinical Medicine</i> , 2018, 7, 216.	2.4	7
74	Cholinergic innervation and ganglion cell distribution in Hirschsprung's disease. <i>BMC Pediatrics</i> , 2020, 20, 399.	1.7	7
75	Genetic and epigenetic characterization of posterior pituitary tumors. <i>Acta Neuropathologica</i> , 2021, 142, 1025-1043.	7.7	7
76	ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. <i>Oncology Letters</i> , 2017, 14, 5443-5451.	1.8	6
77	Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death. <i>Cancers</i> , 2020, 12, 2144.	3.7	6
78	Neurotoxicity of subarachnoid Gd-based contrast agent accumulation: a potential complication of intraoperative MRI?. <i>Neurosurgical Focus</i> , 2021, 50, E12.	2.3	6
79	TGF $\beta$ 2 activates pericytes via induction of the epithelial-mesenchymal transition protein SLUG in glioblastoma. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 768-780.	3.2	6
80	Meningioma Surgery in Patients $\geq$ 70 Years of Age: Clinical Outcome and Validation of the SKALE Score. <i>Journal of Clinical Medicine</i> , 2021, 10, 1820.	2.4	5
81	The Acute Superficial Siderosis Syndrome – Clinical Entity, Imaging Findings, and Histopathology. <i>Cerebellum</i> , 2023, 22, 296-304.	2.5	5
82	Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 165-179.	3.2	4
83	Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 379-393.	3.2	4
84	HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. <i>Neuro-Oncology</i> , 2022, , .	1.2	4
85	Postoperative outcomes and surgical ratio at a newly established epilepsy center: The first 100 procedures. <i>Epilepsy and Behavior</i> , 2021, 116, 107715.	1.7	3
86	A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2373-2383.	2.5	2
87	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. <i>Neurology</i> , 2022, 98, .	1.1	2
88	Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3050.	3.7	1
89	Persistent bowel dysfunction after surgery for Hirschsprung's disease: A neuropathological perspective. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 822-833.	1.5	1
90	Blood Pressure Lowering Decreases Intracerebral Hemorrhage Volume and Improves Behavioral Outcomes in Experimental Animals. <i>Journal of Stroke</i> , 2020, 22, 416-418.	3.2	1